Analysis of differences between imported and domestic imatinib/Gleevec

Imatinib/Gleevec (Imatinib) is a targeted therapy drug mainly used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST). Chronic myeloid leukemia is a type of leukemia originating from bone marrow. Imatinib blocks the proliferation of cancer cells by inhibiting the action of BCR-ABL tyrosine kinase, significantly improving the survival of patients. In the treatment of gastrointestinal stromal tumors, imatinib can effectively inhibit the growth and spread of tumor cells.

Imatinib has a remarkable therapeutic effect and has become a standard drug for the treatment of chronic myelogenous leukemia. It can significantly reduce the number of leukemia cells in patients and improve their quality of life and survival. In addition, imatinib is also used in the adjuvant treatment of some other malignant tumors, especially for patients with poor efficacy of other targeted drugs, imatinib has become an important treatment option.

As for the market price, the price of imported imatinib (Gleevec) is relatively high. Usuallythe packaged price of 60 capsules of 100mg is about 2,000 yuan in China. This price may put a lot of financial pressure on many patients, especially those who need to take it for a long time. On the other hand, the price of generic imatinib produced in countries such as India is relatively cheap. The price of a package of 100 mg and 120 tablets is about three to four hundred yuan. These generic drugs are similar in quality to the original drugs and have undergone strict international certification, becoming an alternative choice for patients with heavy financial burdens.

For domestic patients, imatinib is currently included in medical insurance, and the specific reimbursement policy and reimbursement ratio will vary depending on the region. The coverage of medical insurance greatly reduces the financial burden of patients, especially patients who require long-term treatment can receive more financial support. However, the specific process and reimbursement ratio of medical insurance reimbursement still require patients to consult according to the specific policies of their region.

Reference materials:https://www.gleevec.com/